ClinicalTrials.gg
CompletedNCT00883168Updated Jun 24, 2013Results posted

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

A Phase 3 interventional study of Placebo and azelastineHcl in Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 45 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.

Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,791
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.

Enrollment
Largest of 16
1,791 · median 415
Started
2009
the only one that year
Phase 3
9 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
7 of 16
Meda Pharmaceuticals

Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one has the largest enrollment, is the only one that started in 2009, is one of 9 in phase 3, and was the 8th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About azelastine

azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).

Read the detailed description

This will be a Phase III, randomized, double-blind, placebo-controlled, parallel-group study in subjects with moderate-to-severe seasonal allergic rhinitis (SAR). The study will begin with a 7-day, single-blind, placebo lead-in period (Day -7 to Day 1). Subjects will be instructed to take placebo lead-in medication twice daily (1 spray per nostril), approximately every 12 hours. On Day 1, subjects who satisfy the symptom severity requirements and continue to meet all of the study inclusion/exclusion criteria will be randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02, azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.

Efficacy will be assessed by the change from baseline in the subject-reported 12-hour reflective Total Nasal Symptom Score (TNSS). On Days 1 through 14, subjects will rate the instantaneous and reflective TNSS symptoms of sneezing, nasal congestion, runny nose, and nasal itching; the instantaneous and reflective total ocular symptom score (TOSS) symptoms of itchy eyes, watery eyes and eye redness; the symptom of postnasal drip will be reflectively, twice daily (AM and PM) in a diary prior to the dose of study medication. Symptoms will be scored on a 0 to 3 scale (0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms), such that the maximum daily symptom severity score will be 24 for the TNSS and 18 for the TOSS. Additional secondary efficacy variables will include reflective individual nasal and ocular symptom scores, as well as change from Baseline to Day 14 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

Subjects ≥ 18 years of age will complete the RQLQ on Day 1 (prior to dosing) and Day 14. Subjects will return to the clinic on Day 7 for an interim evaluation. After completing the 2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at time of early termination) for an end-of-study evaluation. Safety and tolerability assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject-reported adverse events (AEs), nasal examinations, and vital signs assessments

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female subjects 12 years of age and older
  2. Provide written /pediatric assent.
  3. Subjects must have moderate-to-severe rhinitis, with one or more of the following present:

    1. Sleep disturbance
    2. Impairment of daily activities, leisure and/or sport
    3. Impairment of school or work
    4. Troublesome symptoms
  4. Screening Visit: Have a 12-hour reflective TNSS of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Visit 1
  5. Randomization Visit: For the 3 days prior to Randomization and on the morning of Randomization, the sum of the 7 consecutive reflective AM and PM TNSS assessments shall be equal to or greater than 56, with a nasal congestion score equal to or greater than 14
  6. Randomization Visit: instantaneous TNSS score of at least 8 and a congestion score of at least 2 just prior to beginning the onset of action assessment
  7. Have taken at least 10 doses of the lead-in medication
  8. Willing and able to comply with the study requirements
  9. At least a 2-year history of SAR during the current allergy season
  10. The presence of IgE-mediated to a prevailing, individual, seasonal pollen, confirmed by a positive response to skin prick within the last year.
  11. General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results.
  12. Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit
  13. Subjects currently receiving sublingual immunotherapy are excluded. A 6-month is required following the last dose of sublingual immunotherapy.

Exclusion criteria

Exclusion Criteria:

  1. On Focused Nasal Examination, the presence of any superficial and moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1b - 4) at either the screening visit or randomization visit will disqualify the subject from the study.
  2. Other nasal disease(s) likely to affect deposition of intranasal medication.
  3. Nasal surgery or sinus surgery within the previous year.
  4. Chronic sinusitis - more than 3 episodes per year
  5. Planned travel outside of the pollen area during the study period
  6. The use of any drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
  7. Presence of any to drugs similar to azelastine hydrochloride or fluticasone propionate
  8. Women who are pregnant or nursing
  9. Women of who are not abstinent or not practicing a medically acceptable method of * see section 6.1.1
  10. Respiratory Tract Infections within 14 days prior to Visit 1
  11. Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Visit 1
  12. Asthma (with the exception of intermittent asthma).
  13. Significant pulmonary disease including
  14. arrhythmia or symptomatic cardiac conditions
  15. A known history of alcohol or drug abuse within the last 2 years
  16. Existence of any surgical or medical condition or physical or laboratory findings, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial.
  17. Patients with a history of glaucoma
  18. Clinically relevant abnormal physical findings within 1 week of randomization may preclude compliance with the study procedures
  19. Employees of the research center or private practice and their family members
  20. no more than 50% of their subjects have participated in protocol MP4001, MP4002 or MP4004
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,791 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: Placebo

  • Active comparator
    azelastine Hcl

    Drug: azelastineHcl

  • Active comparator
    fluticasone propionate

    Drug: fluticasone propionate

  • Experimental
    azelastine Hcl /fluticasone propionate

    Drug: azelastine Hcl/fluticasone propionate

Interventions

  • DrugPlacebo

    Placebo

  • azelastine hydrochloride 548 mg

    Also known as: astelin

  • fluticasone propionate 200 mcg

  • Drugazelastine Hcl/fluticasone propionate

    Drug pages: Azelastine · Fluticasone

    azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg

    Also known as: MP29-02

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)

    change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.

    Time frame: day 1 to day 14

Secondary outcomes

  1. Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)

    change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.

    Time frame: day 1 to day 14

  2. Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

    adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.

    Time frame: day 1 to day 14

07

Results

Posted Sep 7, 2012

Participant flow

Participant flow — Overall Study
MilestoneMP29-02Azelastine HclFluticasone PropionatePlacebo
Started448445450448
Completed434430431433
Not completed14151915

Outcome measures

PrimaryChange From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)

change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.

Time frame:
day 1 to day 14
Reported as:
Least squares mean · units on a scale
Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)
units on a scaleMP29-02Azelastine HclFluticasone PropionatePlacebo
Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)-5.5 ± 5.2-4.8 ± 4.8-4.9 ± 4.7-3.4 ± 4.3
SecondaryChange From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)

change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.

Time frame:
day 1 to day 14
Reported as:
Least squares mean · units on a scale
Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
units on a scaleMP29-02Azelastine HclFluticasone PropionatePlacebo
Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)-5.0 ± 5.3-4.3 ± 4.9-4.7 ± 4.9-3.1 ± 4.4
SecondaryChange From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.

Time frame:
day 1 to day 14
Reported as:
Least squares mean · units on a scale
Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
units on a scaleMP29-02Azelastine HclFluticasone PropionatePlacebo
Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)-1.6 ± 1.3-1.4 ± 1.3-1.6 ± 1.2-1.0 ± 1.2

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MP29-02—1/448 (0.2%)57/448 (12.7%)
Azelastine Hcl—0/449 (0%)47/449 (10.5%)
Fluticasone Propionate—0/450 (0%)32/450 (7.1%)
Placebo—1/451 (0.2%)26/451 (5.8%)
Most frequent serious events
Most frequent serious events
EventMP29-02Azelastine HclFluticasone PropionatePlacebo
lacerated right handInjury, poisoning and procedural complications1/4480/4490/4500/451
pyogenic arthritis right elbowInfections and infestations0/4480/4490/4501/451
Most frequent other events
Most frequent other events
EventMP29-02Azelastine HclFluticasone PropionatePlacebo
dysgusiaGastrointestinal disorders21/44823/4491/4500/451
headacheNervous system disorders10/44814/4498/4504/451
epistaxisRespiratory, thoracic and mediastinal disorders10/4486/4496/4508/451
oropharyngial painGeneral disorders5/4482/4496/4502/451
somnolenceNervous system disorders5/4482/4490/4501/451
mucosal erosionRespiratory, thoracic and mediastinal disorders2/4480/4495/4501/451
nasopharyngitisInfections and infestations3/4480/4493/4505/451
sinus headacheNervous system disorders1/4480/4493/4505/451

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MP29-02Azelastine HclFluticasone PropionatePlaceboTotal
<=18 years57385646197
Between 18 and 65 years3823903903871549
>=65 years91741545
Age Continuous
Age Continuous(years)MP29-02Azelastine HclFluticasone PropionatePlaceboTotal
Mean35.6 ± 14.536.4 ± 14.834.2 ± 14.534.7 ± 14.135.2 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)MP29-02Azelastine HclFluticasone PropionatePlaceboTotal
Female2772712802691097
Male171174170179694
Region of Enrollment
Region of Enrollment(participants)MP29-02Azelastine HclFluticasone PropionatePlaceboTotal
United States4484454504481791
08

Study locations

45 sites
  • Allergy, Asthma and Immunology Associates
    Scottsdale, Arizona 85251, United States
  • Clinical Research Center
    Encinitas, California 92024, United States
  • AABI Associates Medical Group
    Fountain Valley, California 92708, United States
  • Allergy & Asthma Care Center of So. Cal
    Long Beach, California 90808, United States
  • Allergy Research Foundation
    Los Angeles, California 90025, United States
  • Southern California Research
    Mission Viejo, California 92691, United States
  • Allergy Associates Medical Group Inc
    San Diego, California 92120, United States
  • Allergy and Asthma Medical Group and Research Center
    San Diego, California 92123, United States
  • Bensch Research Associates
    Stockton, California 95207, United States
  • Allergy and Asthma Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Asthma and Allergy Associates
    Colorado Springs, Colorado 80907, United States
  • Storms Clinical Research Institute
    Colorado Springs, Colorado 80907, United States
  • Colorado Allergy and Asthma Centers
    Denver, Colorado 80230, United States
  • Clinical Research Atlanta
    Atlanta, Georgia 30342, United States
  • Sneeze, Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Kansas City Allergy and Asthma
    Overland Park, Kansas 66210, United States
  • Family Allergy and Asthma Reserach
    Louisville, Kentucky 40215, United States
  • Northeast Medical Research Associates
    North Dartmouth, Massachusetts 02747, United States
  • Clinical Reseacrh Institute
    Minneapolis, Minnesota 55402, United States
  • The Clinical Research Center
    St. Louis, Missouri 63141, United States
  • The Asthma and Allergy Center
    Papillion, Nebraska 68046, United States
  • Atlantic Research Center
    Ocean, New Jersey 07712, United States
  • Princeton Center for Clinical Research
    Skillman, New Jersey 08558, United States
  • Research Asthma, Sinus and Allergy Centers
    Warren, New Jersey 07059, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45231, United States
  • Allergy, Asthma and Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Clinical Research Institute of Southern Oregon, PC
    Medford, Oregon 97504, United States
  • Allergy and Consultants of NJ/PA
    Collegeville, Pennsylvania 19426, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • National Allergy, Asthma and Urticaria of Charleston
    Charleston, South Carolina 29407, United States
  • East Tennesse Center for Clinical Research
    Knoxville, Tennessee 37909, United States
  • Allergy and Asthma Associates
    Austin, Texas 78731, United States
  • Allergy and Asthma Center of Austin
    Austin, Texas 78759, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Pharmaceutical Research & Consulting Inc
    Dallas, Texas 75231, United States
  • Western Sky Medical Research
    El Paso, Texas 79902, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Diagnostic Research Group
    San Antonio, Texas 78229, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Allergy, Asthma Research Center
    San Antonio, Texas 78258, United States
  • Allergy and Asthma Center
    Waco, Texas 76712, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
  • Intermountain Clinical Research
    Draper, Utah 84020, United States
  • Asthma, Inc.
    Seattle, Washington 98105, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years 2 months after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2009
First posted
Apr 17, 2009
Start
Apr 2009
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results delay requested
Jun 23, 2011
Results first posted
Sep 7, 2012
Last update
Jun 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00883168
Responsible party
Sponsor
First posted
Apr 17, 2009
Start date
Apr 2009
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Sep 7, 2012
Last update
Jun 24, 2013

Study contacts

Lewis M Fredane, MD
study director · Meda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azelastine · Fluticasone

Start the discussion